Join
Live feed
·
PRReleasevia Quantisnow
Roivant Sciences Ltd. logo

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

ByQuantisnow·Wall Street's wire, on your screen.
ROIV· Roivant Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ROIV (Roivant Sciences Ltd.) and more on Quantisnow.